Company intelligence / Profile preview
Resolute Science
San Diego, California, United Statesresolutescience.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Resolute Science is advancing its lead asset, RS-5, a MAC-TAC carrying an MMAE payload that has shown profound single-agent anti-cancer efficacy in preclinical studies. The company is currently conducting IND-enabling studies[5].
- Therapeutic areas
- Oncology
- Modalities
- Synthetic drug conjugatesMacrophage Targeted Conjugates (MAC-TACs)Radiopharmaceuticals
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Beyond the preview
Go deeper on Resolute Science.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Resolute Science.